Taika Capital LP Makes New $369,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Taika Capital LP purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,112 shares of the company's stock, valued at approximately $369,000.

A number of other large investors also recently modified their holdings of the business. Roberts Glore & Co. Inc. IL increased its holdings in shares of Medpace by 2.0% during the fourth quarter. Roberts Glore & Co. Inc. IL now owns 4,161 shares of the company's stock valued at $1,383,000 after purchasing an additional 80 shares during the period. Amundi increased its holdings in shares of Medpace by 1.5% during the fourth quarter. Amundi now owns 4,303 shares of the company's stock valued at $1,526,000 after purchasing an additional 65 shares during the period. Larson Financial Group LLC increased its holdings in shares of Medpace by 9.0% during the fourth quarter. Larson Financial Group LLC now owns 9,509 shares of the company's stock valued at $3,159,000 after purchasing an additional 788 shares during the period. Prescott Group Capital Management L.L.C. increased its holdings in shares of Medpace by 66.7% during the fourth quarter. Prescott Group Capital Management L.L.C. now owns 10,000 shares of the company's stock valued at $3,322,000 after purchasing an additional 4,000 shares during the period. Finally, Lindbrook Capital LLC increased its holdings in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Up 2.2 %

NASDAQ:MEDP opened at $332.81 on Monday. The business's 50-day moving average price is $341.10 and its 200 day moving average price is $342.93. The firm has a market cap of $10.14 billion, a P/E ratio of 26.35, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

Separately, Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.